ASH: Gilead/Arcellx Point To Anito-Cel’s Safety, High-Risk Patient Advantages

 
• By Alaric DeArment
  
Gilead at ASH 2024 (Alaric DeArment/Scrip)

More from Cell Therapies

More from Conferences